Gender and age affect NK1 receptors in the human brain - A positron emission tomography study with [18F]SPA-RQ

International Journal of Neuropsychopharmacology

Volumn 10, Issue 2, 2007, Pages 219-229

  Nyman, Mikko J ^a   Eskola, Olli ^a   Kajander, Jaana ^a   Vahlberg, Tero ^b   Sanabria, Sandra ^c   Burns, Donald ^c   Hargreaves, Richard ^c   Solin, Olof ^a   Hietala, Jarmo ^a,b,d  

^a TURKU PET CENTRE   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c MERCK RESEARCH LABORATORIES   (United States)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Age factors; Gender factors; Human; In vivo; NK1 receptor; Positron emission tomography; Substance P

Indexed keywords

2 FLUOROMETHOXY 5 (5 TRIFLUOROMETHYLTETRAZOL 1 YL)BENZYL (2 PHENYLPIPERIDIN 3 YL)AMINE; [2 FLUOROMETHOXY 5 (5 TRIFLUOROMETHYLTETRAZOL 1 YL)BENZYL] (2 PHENYLPIPERIDIN 3 YL)AMINE F 18; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBELLUM; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GROUPS BY AGE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; MODEL; NEUROBIOLOGY; NEUROPHYSIOLOGY; NORMAL HUMAN; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; RECEPTOR POTENTIAL; REGRESSION ANALYSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SUBICULUM; TEMPORAL CORTEX; VOLUNTEER;

ADULT; AGING; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; DOPAMINE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, NEUROKININ-1; REGRESSION ANALYSIS; SEX CHARACTERISTICS; SUBSTANCE P; TETRAZOLES;

EID: 33847033376     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706006572     Document Type: Article

References (79)

1. Allen JS, Bruss J, Brown CK, Damasio H (2005). Normal neuroanatomical variation due to age: the major lobes and a parcellation of the temporal region. Neurobiology of Aging 26, 1245-1260.
2. Almay BG, Johansson F, Von Knorring L, Le Greves P, Terenius L (1988). Substance P in CSF of patients with chronic pain syndromes. Pain 33, 3-9.
3. Aubry JM, Lundstrom K, Kawashima E, Ayala G, Schulz P, Bartanusz V, Kiss JZ (1994). NK1 receptor expression by cholinergic interneurones in human striatum. Neuroreport 5, 1597-1600.
4. Bailey CP, Maubach KA, Jones RSG (2004). Neurokinin-1 receptors in the rat nucleus tractus solitarius: pre- and postsynaptic modulation of glutamate and GABA release. Neuroscience 127, 467-479.
5. Bannon MJ, Lee JM, Giraud P, Young A, Affolter HU, Bonner TI (1986). Dopamine antagonist haloperidol decreases substance-P, substance-K, and preprotachykinin messenger-RNAs in rat striatonigral neurons. Journal of Biological Chemistry 261, 6640-6642.
6. Bergman J, Eskola O, Lehikoinen P, Solin O (2001). Automated synthesis and purification of [18F]bromofluoromethane at high specific radioactivity. Applied Radiation and Isotopes: Including Data, Instrumentation and Methods for use in Agriculture, Industry and Medicine 54, 927-933.
7. Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Langstrom B, et al. (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry 55, 1007-1012.
8. Buck SH, Deshmukh PP, Burks TF, Yamamura HI (1981). A survey of substance P, somatostatin, and neurotensin levels in aging in the rat and human central nervous system. Neurobiol Aging 2, 257-264.
9. Burnet PW, Harrison PJ (2000). Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biological Psychiatry 47, 80-83.
10. Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R (2003). Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. European Journal of Neuroscience 17, 1736-1746.
11. Carletti R, Corsi M, Melotto S, Caberlotto L (2005). Downregulation of amygdala preprotachykinin A mRNA but not H-3-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. European Journal of Neuroscience 21, 1712-1718.
12. Chen LW, Wei LC, Liu HL, Rao ZR (2000). Noradrenergic neurons expressing substance P receptor (NK1) in the locus coeruleus complex: a double immunofluorescence study in the rat. Brain Research 873, 155-159.
13. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C, Cervero F, Hunt SP (1998). Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392, 394-397.
14. Del Fiacco M, Dessi ML, Levanti MC (1984). Topographical localization of substance P in the human post-mortem brainstem. An immunohistochemical study in the newborn and adult tissue. Neuroscience 12, 591-611.
15. Dupont A, Savard P, Merand Y, Labrie F, Boissier JR (1981). Age-related changes in central nervous system enkephalins and substance P. Life Sciences 29, 2317-2322.
16. Fernandez C, Debeljuk L, Diaz E, Diaz B (2002). Age differences in neurokinin A and substance P from the hypothalamus, pituitary, pineal gland, and striatum of the rat. Effect of exogenous melatonin. Peptides 23, 941-945.
17. Ferrier IN, Cross AJ, Johnson JA, Roberts GW, Crow TJ, Corsellis JAN, Lee YC, O'Shaughnessy D, Adrian TE, McGregor GP, et al. (1983). Neuropeptides in Alzheimer type dementia. Journal of the Neurological Sciences 62, 159-170.
18. Forchetti CM, Marco EJ, Meek JL (1982). Serotonin and gamma-aminobutyric acid turnover after injection into the median raphe of substance P and D-ala-met-enkephalin amide. Journal of Neurochemistry 38, 1336-1341.
19. Friston KJ, Ashburner J, Frith CD, Poline J-P, Heather JD, Frackowiak RSJ (1995). Spatial registration and normalization of images. Human Brain Mapping 3, 165-189.
20. 125I]-Bolton Hunter substance P binding (NK1 receptors) in the basal forebrain nuclei of aged rats. Clinical and Experimental Pharmacology & Physiology 29, 1112-1115.
21. Gerfen CR, McGinty JF, Young III WS (1991). Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. Journal of Neuroscience 11, 1016-1031.
22. Gerfen CR, Young III WS (1988). Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain research 460, 161-167.
23. Gobbi G, Blier P (2005). Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides 26, 1383-1393.
24. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 6, 279-287.
25. 11C]WAY-100635 for PET. NeuroImage 8, 426-440.
26. Haddjeri N, Blier P (2001). Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biological Psychiatry 50, 191-199.
27. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, et al. (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology 21, 4112-4119.
28. Hietala J, Nyman MJ, Eskola O, Laakso A, Grönroos T, Oikonen V, Bergman J, Haaparanta M, Forsback S, Marjamaki P, et al. (In Press). Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Molecular Imaging and Biology.
29. Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, Kishimoto T, Yoshikawa K, Tanada S (2001). Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sciences 69, 1079-1084.
30. Jasmin L, Tien D, Weinshenker D, Palmiter RD, Green PG, Janni G, Ohara PT (2002). The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proceedings of the National Academy of Sciences USA 99, 1029-1034.
31. Kaasinen V, Nagren K, Hietala J, Farde L, Rinne JO (2001). Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. American Journal of Psychiatry 158, 308-311.
32. Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H, Farde L, Rinne J (2000). Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiology of Aging 21, 683-688.
33. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K (In Press). Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry.
34. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt- Knowles E, et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645.
35. Kukuvitis A, Kourtis A, Papaiconomou N, Zournatzi V, Makedos G, Panidis D (2003). Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels. Fertility and Sterility 80, 96-98.
36. Kuppenbender KD, Standaert DG, Feuerstein TJ, Penney JB, Young AB, Landwehrmeyer GB (2000). Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. Journal of Comparative Neurology 419, 407-421.
37. Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvalahti E, Salokangas RK, Hietala J (2002). Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biological Psychiatry 52, 759-763.
38. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4, 153-158.
39. Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA (2003). Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum. Life Sciences 73, 727-739.
40. Lu XY, Ghasemzadeh MB, Kalivas PW (1998). Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience 82, 767-780.
41. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003). An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 19, 1233-1239.
42. Maubach KA, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain CJ, Cumberbatch MJ, Rupniak NMJ, Seabrook GR (2002). Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 109, 609-617.
43. Mazzone SB, Geraghty DP (1999). Altered respiratory response to substance P and reduced NK1 receptor binding in the nucleus of the solitary tract of aged rats. Brain Research 826, 139-142.
44. Meltzer CC, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ, Villemagne VL, Holt D, Mason NS, Houck PR, et al. (2001). Gender-specific aging effects on the serotonin 1A receptor. Brain research 895, 9-17.
45. Meyer JH, Gunn RN, Myers R, Grasby PM (1999). Assessment of spatial normalization of PET ligand images using ligand-specific templates. NeuroImage 9, 545-553.
46. Millan MJ, Lejeune F, De Nanteuil G, Gobert A (2001). Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. Journal of neurochemistry 76, 1949-1954.
47. Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, Sheasby A, Fisher AS, De Felipe C, Mantyh PW, Rupniak NM, et al. (2003). Increased neurogenesis and brainderived neurotrophic factor in neurokinin-1 receptor gene knockout mice. European Journal of Neuroscience 18, 1828-1836.
48. Murtra P, Sheasby AM, Hunt SP, De Felipe C (2000). Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405, 180-183.
49. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, et al. (1999). Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. New England Journal of Medicine 340, 190-195.
50. Otsuka M, Yoshioka K (1993). Neurotransmitter functions of mammalian tachykinins. Physiological Reviews 73, 229-308.
51. Parent A, Cicchetti F, Beach TG (1995). Striatal neurones displaying substance P (NK1) receptor immunoreactivity in human and non-human primates. Neuroreport 6, 721-724.
52. 11]WAY-100635. Brain Research 954, 173-182.
53. Pascual J, Delarco C, Gonzalez AM, Diaz A, Delolmo E, Pazos A (1991). Regionally specific age-dependent decline in alpha-2-adrenoceptors - an autoradiographic study in human brain. Neuroscience Letters 133, 279-283.
54. Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J (1998). Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. American Journal of Psychiatry 155, 768-773.
55. Pompei P, Severini R, Costa G, Massi M, Fattoretti P, Bertoni-Freddari C (1999). In situ hybridization analysis of preprotachykinin-A mRNA levels in young and old rats. Brain Research. Molecular Brain Research 64, 132-136.
56. 11)C]WAY- 100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. NeuroImage 15, 620-632.
57. Rance NE, Young III WS (1991). Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 128, 2239-2247.
58. Reid MS, Herrera-Marschitz M, Hokfelt T, Lindefors N, Persson H, Ungerstedt U (1990). Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Experimental Brain Research 82, 293-303.
59. 11C] raclopride. Journal of Cerebral Blood Flow and Metabolism 13, 310-314.
60. Rinne JO, Lonnberg P, Marjamaki P (1990). Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Research 508, 349-352.
61. Rioux L, Joyce JN (1993). Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 6, 199-210.
62. Rugarn O, Hammar M, Theodorsson E (2001). Progesterone and norethisterone have different effects on tachykinin-like immunoreactivity in rat cortex and striatum. Regulatory Peptides 101, 87-91.
63. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ (2001). Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proceedings of the National Academy of Sciences of the United States of America 98, 1912-1917.
64. Sastre M, Guimon J, Garcia-Sevilla JA (2001). Relationships between beta- and alpha(2)-adrenoceptors and G coupling proteins in the human brain: effects of age and suicide. Brain Research 898, 242-255.
65. Segovia G, Porras A, del Arco A, Mora F (2001). Glutamatergic neurotransmission in aging: a critical perspective. Mechanisms of Ageing and Development 122, 1-29.
66. Sergeyev V, Hokfelt T, Hurd Y (1999). Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 10, 3967-3970.
67. Solin O, Eskola O, Hamill TG, Bergman J, Lehikoinen P, Gronroos T, Forsback S, Haaparanta M, Viljanen T, Ryan C, et al. (2004). Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK(1) receptor quantitation: ([(18)F]SPA-RQ). Molecular Imaging and Biology 6, 373-384.
68. Stoessl AJ, Polanski E, Frydryszak H (1993). Effects of ageing on tachykinin function in the basal ganglia. Brain research 632, 21-28.
69. Stumm R, Culmsee C, Schafer MK, Krieglstein J, Weihe E (2001). Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. Journal of Neuroscience 21, 798-811.
70. Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T, Tateno Y (1991). Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 103, 41-45.
71. Suhara T, Inoue O, Kobayashi K, Suzuki K, Itoh T, Tateno Y (1993). No age-related-changes in human benzodiazepine receptor-binding measured by PET with [C-11] Ro 15-4513. Neuroscience Letters 159, 207-210.
72. Surmeier DJ, Song WJ, Yan Z (1996). Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. Journal of Neuroscience 16, 6579-6591.
73. Villares JC, Stavale JN (2001). Age-related changes in the N-methyl-D-aspartate receptor binding sites within the human basal ganglia. Experimental Neurology 171, 391-404.
74. Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M, Huser JM, Snow BJ, Ruth TJ, Calne DB, Stoessl AJ (1998). Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 30, 56-61.
75. Wang ZP, Man SY, Tang F (1993). Age-related changes in the contents of neuropeptides in the rat brain and pituitary. Neurobiology of Aging 14, 529-534.
76. Whitty CJ, Paul MA, Bannon MJ (1997). Neurokinin receptor mRNA localization in human midbrain dopamine neurons. Journal of Comparative Neurology 382, 394-400.
77. Wong DF, Young D, Wilson PD, Meltzer CC, Gjedde A (1997). Quantification of neuroreceptors in the living human brain: III. D2-like dopamine receptors: theory, validation, and changes during normal aging. Journal of Cerebral Blood Flow and Metabolism 17, 316-330.
78. Yates CM, Harmar AJ, Rosie R, Sheward J, Delevy GS, Simpson J, Maloney AFJ, Gordon A, Fink G (1983). Thyrotropin-releasing-hormone, luteinizing-hormonereleasing hormone and substance-P immuno-reactivity in postmortem brain from cases of Alzheimer-type dementia and Downs syndrome. Brain Research 258, 45-52.
79. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI (1995). Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65, 709-730.